再鼎医药(09688)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09688 再鼎医药

未开盘 01-14 16:08:06

15.480

+0.820

+5.59%

最高15.810	最低14.730	成交量2,723万
今开14.860	昨收14.660	日振幅7.37%
总市值173.38亿	流通市值173.38亿	总股本11.20亿
成交额4.20亿	换手率2.43%	流通股本11.20亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09688","market":"HK","secType":"STK","nameCN":"再鼎医药","latestPrice":15.48,"timestamp":1768378086012,"preClose":14.66,"halted":0,"volume":27227946,"delay":0,"floatShares":1120000000,"shares":1120000000,"eps":-2.0260194931773876,"marketStatus":"未开盘","change":0.82,"latestTime":"01-14 16:08:06","open":14.86,"high":15.81,"low":14.73,"amount":420179291,"amplitude":0.07367,"askPrice":15.49,"askSize":47300,"bidPrice":15.48,"bidSize":5300,"shortable":3,"etf":0,"ttmEps":-1.4993138401559454,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1768440600000},"marketStatusCode":0,"adr":0,"listingDate":1601222400000,"exchange":"SEHK","adjPreClose":14.66,"openAndCloseTimeList":[[1768354200000,1768363200000],[1768366800000,1768377600000]],"volumeRatio":2.230332865617015,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09688","defaultTab":"news","newsList":[{"id":"2603690983","title":"药明生物与再鼎医药就创新T细胞衔接子达成研究服务协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2603690983","media":"人民财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603690983?lang=zh_cn&edition=full","pubTime":"2026-01-14 19:24","pubTimestamp":1768389864,"startTime":"0","endTime":"0","summary":"1月14日，药明生物宣布与再鼎医药已针对一款创新T细胞衔接子（TCE）签署研究服务协议，再鼎医药将获得该TCE在实体瘤适应症治疗上的全球独家开发与商业化权利。该TCE的发现是基于药明生物专有的CD3技术平台，并结合多特异性抗体研究能力和前沿生物学洞见。基于该平台开发的三款TCE分子目前均处于临床开发阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601143619133231.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1588","LU2488822045.USD","LU1720050803.USD","LU1688375341.USD","IE00B0JY6N72.USD","BK4526","BK4585","SG9999002463.SGD","02269","LU0417516738.SGD","LU0516423091.SGD","LU0516422440.USD","LU0320764599.SGD","BK4548","LU0140636845.USD","LU0348825331.USD","LU0572944931.SGD","LU0823426480.USD","LU0456827905.SGD","LU0181495838.USD","LU0039217434.USD","LU0359202008.SGD","LU0052750758.USD","LU3063872942.SGD","BK1589","LU1242518857.USD","LU2039709279.SGD","LU0326950275.SGD","BK1141","ZLAB","LU0588546209.SGD","LU0708995583.HKD","BK4139","LU0516423174.USD","LU0979878070.USD","BK1576","LU0516422952.EUR","BK1574","09688","LU0417516902.SGD","BK1610","LU0819121731.USD","BK4588","LU0307460666.USD","LU0327786744.USD","LU0043850808.USD","LU0456846285.SGD","LU1794554557.SGD","BK4531","BK1161"],"gpt_icon":0},{"id":"2603666362","title":"再鼎医药午前涨超7% 公司亮相JPM医疗健康大会","url":"https://stock-news.laohu8.com/highlight/detail?id=2603666362","media":"新浪港股","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603666362?lang=zh_cn&edition=full","pubTime":"2026-01-14 11:27","pubTimestamp":1768361220,"startTime":"0","endTime":"0","summary":"　　再鼎医药午前股价上涨7.16%，现报15.71港元，成交额1.97亿港元。　　据再鼎医药官微消息，1月13日，公司在第44届摩根大通医疗健康大会上介绍2026年战略重点及临床开发进展，相关内容将于1月14日进行展示。呫诺美林曲司氯铵胶囊预计于2026年上半年通过聚焦、高效的商业化策略上市，重点包括医生教育、真实世界的证据生成以及为2027年有望纳入国家医保药品目录做好准备。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-01-14/doc-inhhfvyz4202820.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU2237443549.SGD","LU2264538146.SGD","BK4533","159760","BK4585","LU2236285917.USD","IE00B1BXHZ80.USD","LU0251132253.USD","XBI","IE00BJTD4V19.USD","LU2746668461.USD","IE00BWXC8680.SGD","LU0149725797.USD","IE00B1XK9C88.USD","BK4207","LU1280957306.USD","LU0942090050.USD","BK1161","LU2756315318.SGD","LU2430703178.SGD","ZLAB","LU0820562030.AUD","IE0034235188.USD","BK4531","LU0345769631.USD","BK1588","LU1894683348.USD","LABU","LU1668664300.SGD","LU2237443978.SGD","LU1366192091.USD","BK4534","LU2430703251.USD","LU0006306889.USD","LU2357305700.SGD","LU0689472784.USD","LU1244550221.USD","IE00BYXW3230.USD","XLV","IE00BN8TJ469.HKD","LU1551013425.SGD","LU0417517546.SGD","BK4566","IE00B3S45H60.SGD","LU2242649171.HKD","LU2456880835.USD","LU1720051108.HKD","LU2106854487.HKD","09688","LU2381873111.SGD"],"gpt_icon":0},{"id":"1136564727","title":"异动解读 | 再鼎医药盘中大涨7.3%，JPM医疗健康大会展示战略重点及临床进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1136564727","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136564727?lang=zh_cn&edition=full","pubTime":"2026-01-14 11:20","pubTimestamp":1768360826,"startTime":"0","endTime":"0","summary":"再鼎医药今日盘中大涨7.3%，引发市场广泛关注。消息面上，再鼎医药在第44届摩根大通医疗健康大会上介绍了2026年战略重点及临床开发进展。其中，Zocilurtatug pelitecan有望成为公司肿瘤领域首款全球上市产品，计划在2026年底前启动三项注册性关键研究，包括二线及以上小细胞肺癌、一线小细胞肺癌和神经内分泌癌。此外，再鼎医药在中国拥有八款商业化产品，形成了多元化且可持续的商业化管线组合。这些进展增强了投资者对公司未来业绩的乐观预期。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09688"],"gpt_icon":0},{"id":"2603866383","title":"港股异动 | 再鼎医药(09688)涨超7% 公司亮相JPM医疗健康大会 Zoci有望成为肿瘤领域首款全球上市产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2603866383","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603866383?lang=zh_cn&edition=full","pubTime":"2026-01-14 11:10","pubTimestamp":1768360208,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，再鼎医药涨超7%，截至发稿，涨7.09%，报15.7港元，成交额1.85亿港元。消息面上，据再鼎医药官微消息，1月13日，公司在第44届摩根大通医疗健康大会上介绍2026年战略重点及临床开发进展，相关内容将于1月14日进行展示。其中，Zocilurtatug pelitecan有望成为再鼎医药肿瘤领域首款全球上市产品，计划在2026年底前启动三项注册性关键研究，包括二线及以上小细胞肺癌、一线小细胞肺癌和神经内分泌癌。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1392604.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ZLAB","LU0417517546.SGD","LU0106261372.USD","LU0265550946.USD","159760","IE00BHPRN162.USD","LU0048584097.USD","LU1670627923.USD","LU1244550221.USD","LU1496350171.SGD","LU2488822045.USD","LU0211326839.USD","LU0964807845.USD","LU1064131342.USD","IE00BN8TJ469.HKD","LU1720051017.SGD","IE00BZ1G4Q59.USD","LU0882574139.USD","IE00BLSP4452.SGD","IE00B1BXHZ80.USD","LU2505996681.GBP","LU0211331839.USD","IE00BWXC8680.SGD","LU1261432733.SGD","LU0320765646.SGD","LU1548497426.USD","BK4548","LU2054465674.USD","IE0034235188.USD","IE00BJTD4N35.SGD","LABU","LU2430703095.HKD","LU0234572021.USD","XLV","BK1588","XBI","LU1032466523.USD","LU2381873111.SGD","LU0820561818.USD","LU2462157665.USD","LU0256863811.USD","LU0238689110.USD","LU1496350502.SGD","IE0034235303.USD","LU0820561909.HKD","BK4585","BK4581","IE00BKVL7J92.USD","LU2756315318.SGD","09688"],"gpt_icon":0},{"id":"2602933518","title":"JPM 2026前瞻 | 中国创新药站上全球舞台中央","url":"https://stock-news.laohu8.com/highlight/detail?id=2602933518","media":"Ofweek光电信息网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602933518?lang=zh_cn&edition=full","pubTime":"2026-01-12 16:58","pubTimestamp":1768208280,"startTime":"0","endTime":"0","summary":"2026年第44届摩根大通医疗健康大会将于1月12日至15日在美国旧金山举行。据披露，本届JPM的议题与参会企业或将高度集中于六大核心领域，其中生物技术板块占比最高，预计接近35%。目前，已有多家国内企业确认参会，且覆盖CXO与创新药两大核心群体。从行业趋势看，本届JPM或将进一步强化两条技术主线。进入2026年，这一趋势仍在延续。宜联生物B7H3 ADC授权给罗氏此次JPM 2026将成为国内药企集中展示核心分子竞争力、推动海外BD合作的重要窗口。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112173836a710ffe8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112173836a710ffe8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","06160","02269","LU2328871848.SGD","03696","BK1583","06978","09995","02359","BK1161","LU1969619763.USD","09688","01530","01276","02615"],"gpt_icon":0},{"id":"2602902425","title":"中国力量在JPM大会的闪耀时刻：24家国产企业双线发力","url":"https://stock-news.laohu8.com/highlight/detail?id=2602902425","media":"药渡","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602902425?lang=zh_cn&edition=full","pubTime":"2026-01-12 16:36","pubTimestamp":1768206992,"startTime":"0","endTime":"0","summary":"而今年，中国力量成为舞台上最耀眼的星光之一：24家国产医药企业集体亮相，以“主会场引领、亚太专场扩容”的双线布局，向世界展示中国医药产业的创新硬实力与全球化野心。结 语从主会场的核心发声到亚太专场的集体亮相，24家中国药企在JPM大会的舞台上，用实打实的研发成果、商业化突破与海外合作，书写着中国医药的全球化篇章。这不仅是中国力量的闪耀时刻，更预示着2026年中国创新药将在全球舞台上迎来更多突破。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112165035a710cae5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112165035a710cae5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1719994722.HKD","LU2328871848.SGD","BK1161","BK1588","LU2488822045.USD","LU1303224171.USD","LU0307460666.USD","BK1574","LU1770034418.SGD","02359","BK1583","01530","BK1500","06990","09995","06160","09688","LU1969619763.USD","LU0588546209.SGD","02269","01276","06978","LU1251922891.USD"],"gpt_icon":0},{"id":"2602590742","title":"每日卖空追踪 | 再鼎医药 01月12日卖空量成交127.39万股，卖空比例为9.95%","url":"https://stock-news.laohu8.com/highlight/detail?id=2602590742","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602590742?lang=zh_cn&edition=full","pubTime":"2026-01-12 16:30","pubTimestamp":1768206640,"startTime":"0","endTime":"0","summary":"再鼎医药北京时间01月12日，跌0.07%，卖空量成交127.39万股，较上一交易日减少68.71%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112165300a4b9d832&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112165300a4b9d832&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1588","BK1574","LU2488822045.USD","BK1161","09688"],"gpt_icon":0},{"id":"2602590216","title":"再鼎医药01月12日遭主力抛售630.1万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2602590216","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602590216?lang=zh_cn&edition=full","pubTime":"2026-01-12 16:15","pubTimestamp":1768205756,"startTime":"0","endTime":"0","summary":"01月12日, 再鼎医药股价跌0.07%，报收14.50元，成交金额1.8亿元，换手率1.14%，振幅3.45%，量比1.15。再鼎医药今日主力资金净流出630.1万元，上一交易日主力净流出1381.6万元。该股近5个交易日上涨1.91%，主力资金累计净流入95.0万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流出1351.3万元，其中净流出天数为8日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112163051a4b9c125&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112163051a4b9c125&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1588","LU2488822045.USD","09688","BK1574"],"gpt_icon":0},{"id":"2602960815","title":"“医药春晚”即将召开！","url":"https://stock-news.laohu8.com/highlight/detail?id=2602960815","media":"科创日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602960815?lang=zh_cn&edition=full","pubTime":"2026-01-12 10:15","pubTimestamp":1768184118,"startTime":"0","endTime":"0","summary":"文|张真当地时间1月12日，全球生物医药行业的“春晚”——第44届摩根大通全球医疗健康大会即将正式在美国召开，预计为期4天。截至目前，已有多家国内创新药企确认参会。除此之外，恒瑞医药、百利天恒、三生制药、荣昌生物等17家国产创新药企也将亮相亚太专场。上述机构进一步指出，BD常态化后，制药行业将回归产品全球价值验证。宜联生物将获得5.7亿美元首付款及近期里程碑付款。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112102905a70f9931&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112102905a70f9931&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09939","BK1574","BK1515","BK1588","LU2488822045.USD","09688"],"gpt_icon":0},{"id":"2602377727","title":"每日卖空追踪 | 再鼎医药 01月09日卖空量成交214万股，卖空比例为15.83%","url":"https://stock-news.laohu8.com/highlight/detail?id=2602377727","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602377727?lang=zh_cn&edition=full","pubTime":"2026-01-09 16:30","pubTimestamp":1767947441,"startTime":"0","endTime":"0","summary":"再鼎医药北京时间01月09日，跌1.69%，卖空量成交214万股，较上一交易日增加5.87%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260109163959a4af866d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260109163959a4af866d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1588","09688","LU2488822045.USD","BK1161"],"gpt_icon":0},{"id":"2602377082","title":"再鼎医药01月09日主力净流出1381.6万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2602377082","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602377082?lang=zh_cn&edition=full","pubTime":"2026-01-09 16:15","pubTimestamp":1767946554,"startTime":"0","endTime":"0","summary":"01月09日, 再鼎医药股价跌1.69%，报收14.51元，成交金额2.0亿元，换手率1.21%，振幅2.44%，量比1.53。再鼎医药今日主力资金净流出1381.6万元，上一交易日主力净流入1020.6万元。该股近5个交易日上涨6.55%，主力资金累计净流入1571.7万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流出506.5万元，其中净流出天数为7日。该股主力净额占比0.09%，港股市场排名2664/2716。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260109162236a4af71e2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260109162236a4af71e2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","LU2488822045.USD","09688","BK1588"],"gpt_icon":0},{"id":"2602884312","title":"【券商聚焦】华泰证券：开年以来的流动性修复有望提振创新药板块β","url":"https://stock-news.laohu8.com/highlight/detail?id=2602884312","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602884312?lang=zh_cn&edition=full","pubTime":"2026-01-09 08:58","pubTimestamp":1767920334,"startTime":"0","endTime":"0","summary":"金吾财讯 | 华泰证券表示，自9月港股创新药年内新高以来，港股创新药指数截止到年底回调24%，而同期美股生物科技指数XBI涨幅29%，NBI指数涨幅18%。XBI自4月底部反弹超过100%，大型MNC普遍自底部反弹30~50%，礼来市值首次突破万亿美金。步入新的一年，港股创新药迎来开门红。随着流动性修复及对外BD持续，以及JPM峰会、年报周期的BD旺季和数据披露高峰的到来，该机构认为开年以来的流动性修复有望提振创新药板块β，上涨趋势有望持续。","market":"sh","thumbnail":"https://static.szfiu.com/news/20241108/MjAwMmJhMzhlMzU2ODgyNzA0NzY4MTcyNA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MjAwMmJhMzhlMzU2ODgyNzA0NzY4MTcyNA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1972900","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1226287792.SGD","09926","LU1064131003.USD","LU0516422440.USD","LU1934453819.USD","IE0008369823.USD","LU3063872942.SGD","LU0315179316.USD","601688","LU0588546209.SGD","01877","BK1589","LU1242518857.USD","LU2476274720.SGD","LU0502904849.HKD","01801","LU0307460666.USD","LU0417516571.SGD","06160","02142","LU2097828474.EUR","LU0561508036.HKD","LU0516423174.USD","01177","06185","09995","LU0039217434.USD","LU1152091168.USD","LU1979443071.USD","IE00B5MMRT66.SGD","09688","BK1141","LU1328277881.USD","LU1993786604.SGD","BK1500","BK0012","02616","LU1807302812.USD","LU2097828805.USD","LU2148510915.USD","LU0067412154.USD","LU1960683339.HKD","LU0516422952.EUR","LU0501845795.SGD","LU0043850808.USD","06978","01093","159992","02269","BK0183"],"gpt_icon":0},{"id":"2602639763","title":"赛生药业获得再鼎医药“瑞普替尼”中国大陆独家推广权","url":"https://stock-news.laohu8.com/highlight/detail?id=2602639763","media":"丁香园 Insight 数据库","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602639763?lang=zh_cn&edition=full","pubTime":"2026-01-08 11:52","pubTimestamp":1767844349,"startTime":"0","endTime":"0","summary":"1 月 8 日消息，赛生药业宣布已于近日与再鼎医药达成合作，获得新一代酪氨酸激酶抑制剂 瑞普替尼在中国大陆的独家推广权，双方将携手推进该创新药物在中国市场的商业化。2020 年 7 月，再鼎医药与 Turning Point达成一项1.76 亿美元的独家授权协议，获得瑞普替尼在大中华区的独家开发及商业化权。2024 年 5 月，瑞普替尼获中国 NMPA 批准上市，用于治疗ROS1 阳性的局部晚期或转移性非小细胞肺癌成人患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108140004a4aab112&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108140004a4aab112&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2488822045.USD","BK1191","BK1161","09688","BK1574","BK1588"],"gpt_icon":1},{"id":"1162544881","title":"再鼎医药（09688）更新2025年12月股份变动月报表 股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1162544881","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162544881?lang=zh_cn&edition=full","pubTime":"2026-01-07 17:31","pubTimestamp":1767778275,"startTime":"0","endTime":"0","summary":"再鼎医药有限公司于2026年1月7日披露截至2025年12月31日的股份变动月报表。公告显示，公司期内法定股本及已发行股份总数均保持不变。激励计划方面，2025年12月涉及部分股权激励计划的期权行使及限制性股票单位归属均通过现有已发行股份兑现，并未导致已发行股份总数增加；少量无归属期权及RSU则宣告失效，对当月股本无任何影响。公司指出，当月行使期权所获得款项约6,510.24美元。公告由公司董事杜瑩签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09688"],"gpt_icon":0},{"id":"2601767758","title":"每日卖空追踪 | 再鼎医药 01月07日卖空量成交232.99万股，卖空比例为18.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601767758","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601767758?lang=zh_cn&edition=full","pubTime":"2026-01-07 16:30","pubTimestamp":1767774643,"startTime":"0","endTime":"0","summary":"再鼎医药北京时间01月07日，涨2.78%，卖空量成交232.99万股，较上一交易日增加14.66%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260107163644a6fde155&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260107163644a6fde155&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09688","BK1588","BK1574","LU2488822045.USD","BK1161"],"gpt_icon":0},{"id":"2601987676","title":"再鼎医药01月07日获主力加仓757.8万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2601987676","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601987676?lang=zh_cn&edition=full","pubTime":"2026-01-07 16:15","pubTimestamp":1767773742,"startTime":"0","endTime":"0","summary":"01月07日, 再鼎医药股价涨2.78%，报收14.80元，成交金额1.9亿元，换手率1.15%，振幅3.40%，量比1.67。再鼎医药今日主力资金净流入757.8万元，连续4日净流入，上一交易日主力净流入328.2万元。近一年数据显示，该股主力连续4日净流入后，次日上涨概率为50.00%，平均涨幅为4.67%。该股近5个交易日上涨7.25%，主力资金累计净流入1228.7万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入299.2万元，其中净流入天数为14日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260107161927a6fdcb25&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260107161927a6fdcb25&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1588","09688","LU2488822045.USD","BK1161"],"gpt_icon":0},{"id":"2601841928","title":"再鼎医药01月06日获主力加仓328.2万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2601841928","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601841928?lang=zh_cn&edition=full","pubTime":"2026-01-06 16:15","pubTimestamp":1767687334,"startTime":"0","endTime":"0","summary":"01月06日, 再鼎医药股价涨1.62%，报收14.40元，成交金额1.3亿元，换手率0.79%，振幅2.89%，量比0.92。再鼎医药今日主力资金净流入328.2万元，连续3日净流入，上一交易日主力净流入846.7万元。近一年数据显示，该股主力连续3日净流入后，次日上涨概率为68.75%，平均涨幅为3.37%。该股近5个交易日上涨4.56%，主力资金累计净流出3286.8万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流出213.4万元，其中净流出天数为6日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106161807a6f97115&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106161807a6f97115&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09688","BK1574","BK1588","LU2488822045.USD","BK1161"],"gpt_icon":0},{"id":"2601830324","title":"不限癌种！再鼎医药“瑞普替尼”新适应症国内获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2601830324","media":"丁香园 Insight 数据库","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601830324?lang=zh_cn&edition=full","pubTime":"2026-01-05 18:04","pubTimestamp":1767607477,"startTime":"0","endTime":"0","summary":"作为新一代 ROS1 和 NTRK TKI，瑞普替尼的独特设计可用于改善包括脑部在内的获益持久性。瑞普替尼NTRK 阳性实体瘤适应症在美国的获批是基于 I/II 期 TRIDENT-1 研究的积极结果，该研究旨在评估瑞普替尼在 NTRK 阳性成人实体瘤患者中的疗效。截图来源：Insight 数据库在国内，瑞普替尼于 2024 年 5 月首次获得 NMPA 批准上市，用于局部晚期或转移性 ROS1 阳性 NSCLC成人患者。本次是瑞普替尼在国内获批的第 2 项适应症。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105184353a49ea968&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105184353a49ea968&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","LU2488822045.USD","BK1574","09688","BK1588"],"gpt_icon":0},{"id":"2601830315","title":"每日卖空追踪 | 再鼎医药 01月05日卖空量成交89.69万股，卖空比例为8.58%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601830315","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601830315?lang=zh_cn&edition=full","pubTime":"2026-01-05 16:30","pubTimestamp":1767601841,"startTime":"0","endTime":"0","summary":"再鼎医药北京时间01月05日，涨4.34%，卖空量成交89.69万股，较上一交易日增加45.84%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105163831a49e2cc9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105163831a49e2cc9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09688","BK1588","BK1574","BK1161","LU2488822045.USD"],"gpt_icon":0},{"id":"2601830376","title":"再鼎医药01月05日获主力加仓846.7万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2601830376","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601830376?lang=zh_cn&edition=full","pubTime":"2026-01-05 16:15","pubTimestamp":1767600923,"startTime":"0","endTime":"0","summary":"01月05日, 再鼎医药股价涨4.34%，报收14.17元，成交金额1.5亿元，换手率0.93%，振幅6.85%，量比0.80。再鼎医药今日主力资金净流入846.7万元，上一交易日主力净流入174.9万元。该股近5个交易日下跌2.14%，主力资金累计净流出3465.0万元；近20日主力资金累计净流出535.3万元，其中净流出天数为6日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105161701a49e12de&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105161701a49e12de&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09688","BK1588","LU2488822045.USD","BK1574"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.zailaboratory.com","stockEarnings":[{"period":"1week","weight":0.0459},{"period":"1month","weight":0.1234},{"period":"3month","weight":-0.3362},{"period":"6month","weight":-0.4309},{"period":"1year","weight":-0.2021},{"period":"ytd","weight":0.1341}],"compareEarnings":[{"period":"1week","weight":0.0204},{"period":"1month","weight":0.0535},{"period":"3month","weight":0.0429},{"period":"6month","weight":0.0876},{"period":"1year","weight":0.4048},{"period":"ytd","weight":0.0534}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"再鼎医药有限公司是一家主要从事生物制药的控股公司。该公司致力于通过产品的发现、开发和商业化解决肿瘤、自身免疫疾病、感染性疾病和中枢神经系统疾病领域未被满足的医疗需求。该公司拥有从发现阶段到临床项目后期的一系列专利候选药物。其中包括“则乐”、“OPTUNE”、“擎乐”、“纽再乐”及“卫伟迦”等。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.011339},{"month":2,"riseRate":0.6,"avgChangeRate":0.053227},{"month":3,"riseRate":0.2,"avgChangeRate":-0.100669},{"month":4,"riseRate":0.6,"avgChangeRate":0.032813},{"month":5,"riseRate":0.4,"avgChangeRate":-0.024133},{"month":6,"riseRate":0.4,"avgChangeRate":-0.013792},{"month":7,"riseRate":0.8,"avgChangeRate":0.065752},{"month":8,"riseRate":0.6,"avgChangeRate":-0.021717},{"month":9,"riseRate":0.4,"avgChangeRate":-0.054178},{"month":10,"riseRate":0.5,"avgChangeRate":-0.051338},{"month":11,"riseRate":0.5,"avgChangeRate":0.047251},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.024481}],"exchange":"SEHK","name":"再鼎医药","nameEN":"ZAI LAB"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"再鼎医药(09688)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供再鼎医药(09688)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"再鼎医药,09688,再鼎医药股票,再鼎医药股票老虎,再鼎医药股票老虎国际,再鼎医药行情,再鼎医药股票行情,再鼎医药股价,再鼎医药股市,再鼎医药股票价格,再鼎医药股票交易,再鼎医药股票购买,再鼎医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"再鼎医药(09688)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供再鼎医药(09688)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}